ProstaScint^®

ProstaScint is an imaging agent that can help locate and identify the extent of prostate cancer. It also helps identify previously diagnosed prostate cancer that has spread (metastasized) to other areas within the body, such as the lymph nodes, adjacent tissue and bone. ProstaScint is a single clone (monoclonal) antibody that is combined with a small amount of radioactive material called Indium 111. Given by injection into a vein, ProstaScint circulates throughout the body and attaches to an antigen called PSMA (Prostate Specific Membrane Antigen), which is located on prostate cancer cells. Pictures or images are then taken with a special device called a gamma camera that can detect radiation given off by the Indium 111. Using this technology, pictures or images will be produced showing prostate cancer.

ProstaScint can be used in newly-diagnosed prostate cancer patients with biopsy-proven prostate cancer, who are at high-risk for pelvic lymph node cancer growth. ProstaScint is also recommended for use in post-prostatectomy patients with a rising PSA (Prostate Specific Antigen) in whom there is a high medical suspicion of metastatic disease. Patient management should not be based on ProstaScint scan results without additional verification.

ProstaScint is available in the U.S. For more information on ProstaScint please visit ProstaScintimaging.com.

USA - Important Safety Information:
Patient management should not be based on ProstaScint scan results without appropriate confirmatory studies since in the pivotal trials, there was a high rate of false positive and false negative image interpretations. ProstaScint images should be interpreted only by physicians who have had specific training in ProstaScint® image interpretation. Medications for the treatment of hypersensitivity reactions should be available during administration of this agent.

For information on our full range of products, where they are available and prescribing information, please see the Summary table.